Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | DDB1 | Q16531 | 6/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 6/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11917928 | 1.00 | ALDH1A1 (0.34) | ALDH1A1SMN1; SMN2LMNATDP1DDB1 | |
| SCHEMBL14916972 | 1.00 | ALDH1A1 (0.34) | ALDH1A1SMN1; SMN2LMNATDP1DDB1 | |
| SCHEMBL8250045 | 0.86 | CRBN (0.33) | CRBN | |
| SCHEMBL7621561 | 0.85 | CA1 (0.35) | ALDH1A1CRBNKMT2A | |
| SCHEMBL18686236 | 0.82 | ALDH1A1 (0.33) | ALDH1A1SMN1; SMN2LMNATDP1 | |
| SCHEMBL20213478 | 0.82 | ALDH1A1 (0.33) | ALDH1A1SMN1; SMN2LMNATDP1DDB1 | |
| SCHEMBL16097469 | 0.82 | LMNA (0.37) | ALDH1A1SMN1; SMN2LMNATDP1 | |
| SCHEMBL16097473 | 0.82 | LMNA (0.37) | ALDH1A1SMN1; SMN2LMNATDP1 | |
| SCHEMBL18943659 | 0.82 | LMNA (0.34) | ALDH1A1SMN1; SMN2LMNATDP1 | |
| SCHEMBL14415910 | 0.79 | LMNA (0.33) | ALDH1A1SMN1; SMN2LMNACRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037354-B2 | Cyclic pantetheine derivatives and uses thereof | VECTIVBIO COMET AG (CH) | 2024-07-16 | — | — | US | disclosed |
| US-12037354-B2 | Cyclic pantetheine derivatives and uses thereof | VECTIVBIO COMET AG (CH) | 2024-07-16 | — | — | US | disclosed |
| US-20230373963-A1 | 3-[(1H-PYRAZOL-R-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF | BEIGENE, LTD. (KY) | 2023-11-23 | — | — | US | disclosed |
| US-20230373963-A1 | 3-[(1H-PYRAZOL-R-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF | BEIGENE, LTD. (KY) | 2023-11-23 | — | — | US | disclosed |
| US-11802125-B2 | Functionalized heterocyclic compounds as antiviral agents | ENANTA PHARMACEUTICALS, INC. | 2023-10-31 | — | — | US | disclosed |
| US-11802125-B2 | Functionalized heterocyclic compounds as antiviral agents | ENANTA PHARMACEUTICALS, INC. | 2023-10-31 | — | — | US | disclosed |
| US-11782345-B2 | Bottom antireflective coating materials | TAIWAN SEMICONDUCTOR MANUFACTURING CO., LTD. (TW) | 2023-10-10 | — | — | US | disclosed |
| WO-2023192479-A1 | TRICYCLIC IRAK INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-11738019-B2 | Substituted heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20230150972-A1 | PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | XENON PHARMACEUTICALS INC. (CA) | 2023-05-18 | — | — | US | disclosed |
| US-20070203183-A1 | Diaryl piperidines as CB1 modulators | SCHERING CORPORATION | 2007-08-30 | — | — | US | disclosed |
| US-20070179167-A1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-02 | — | — | US | disclosed |
| US-7250437-B2 | Small molecule modulators of hepatocyte growth factor (scatter factor) activity | ANGION BIOMEDICA CORP. (US) | 2007-07-31 | — | — | US | disclosed |
| US-20070161789-A1 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED | 2007-07-12 | — | — | US | disclosed |
| US-7241796-B2 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INC. (US) | 2007-07-10 | — | — | US | disclosed |
| US-20070105781-A1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-05-10 | — | — | US | disclosed |
| US-7208600-B2 | Inhibitors of serine proteases, particularly HCV NS3-NS4A proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-04-24 | — | — | US | disclosed |
| US-20070087973-A1 | producing (1S,3aR,6aS)-2-((S)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide, used as serine protease inhibitors, useful for treatment of hepatitis C virus infections | VERTEX PHARMACEUTICALS INCORPORATED | 2007-04-19 | — | — | US | disclosed |
| US-20070087973-A1 | producing (1S,3aR,6aS)-2-((S)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide, used as serine protease inhibitors, useful for treatment of hepatitis C virus infections | VERTEX PHARMACEUTICALS INCORPORATED | 2007-04-19 | — | — | US | disclosed |
| US-7192976-B2 | 3-substituted pyrazoles; cell proliferation and angiogenesis promoters; antiapoptotosis and antifibrosis activity | ANGION BIOMEDICA CORPORATION (US) | 2007-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203183-A1 | Diaryl piperidines as CB1 modulators | CNR1, CNR2, GPR119 | ALDH1A1 1216/4885SMN1; SMN2 3353/4885LMNA 3607/4885 |
| US-11802125-B2 | Functionalized heterocyclic compounds as antiviral agents | HAVCR2, HDGF, HCCS | ALDH1A1 2297/4885SMN1; SMN2 4605/4885LMNA 2254/4885 |
| US-20230373963-A1 | 3-[(1H-PYRAZOL-R-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF | HIPK1, HIPK3, HIPK2 | ALDH1A1 3197/4885SMN1; SMN2 3720/4885LMNA 3278/4885 |
| US-20070087973-A1 | producing (1S,3aR,6aS)-2-((S)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide, used as serine protease inhibitors, useful for treatment of hepatitis C virus infections | PRSS1, CTRL, TMPRSS2 | ALDH1A1 599/4885SMN1; SMN2 3849/4885LMNA 2536/4885 |
| US-20070105781-A1 | Inhibitors of serine proteases | PRSS1, SERPINB1, PRSS3 | ALDH1A1 2154/4885SMN1; SMN2 1946/4885LMNA 1456/4885 |
| US-20070161789-A1 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | PRSS1, SERPINB1, SPINT2 | ALDH1A1 1658/4885SMN1; SMN2 1613/4885LMNA 1714/4885 |
| US-20070179167-A1 | Inhibitors of serine proteases | PRSS1, PRSS3, PRSS2 | ALDH1A1 1374/4885SMN1; SMN2 2265/4885LMNA 2814/4885 |
| US-12037354-B2 | Cyclic pantetheine derivatives and uses thereof | VNN1, VKORC1, PANK3 | ALDH1A1 758/4885SMN1; SMN2 3480/4885LMNA 1802/4885 |
| US-11738019-B2 | Substituted heterocycles as antiviral agents | HCCS, HDGF, HAVCR2 | ALDH1A1 2798/4885SMN1; SMN2 4681/4885LMNA 2465/4885 |
| US-20230150972-A1 | PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | SCN1B, SCN1A, SCN2B | ALDH1A1 1828/4885SMN1; SMN2 564/4885LMNA 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.